Rigel Pharmaceuticals Inc (RIGL) Stock Price & Analysis
Rigel Pharmaceuticals Inc (RIGL) fell 0.22% to USD 36.74 as of July 25, 2026 at 06:46 UTC, according to Nexqual real-time market data.
RIGL last closed at USD 36.82; the session ranged USD 35.01–37.05 on volume of 472,082 shares. Market capitalization is $679.77M, with a 52-week range of USD 19.51–52.24 (NMS). Source: Nexqual, July 25, 2026 at 06:46 UTC.
Key Statistics (as of July 25, 2026 at 06:46 UTC)
| Price | USD 36.74 |
|---|---|
| Change | ▼ 0.22% (down) |
| Previous Close | USD 36.82 |
| Open | USD 36.82 |
| Day Range | USD 35.01 – 37.05 |
| 52-Week Range | USD 19.51 – 52.24 |
| Volume | 472,082 shares |
| Market Cap | $679.77M |
| Exchange | NMS |
Technical Analysis (RIGL)
Nexqual's technical model rates RIGL "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 06:46 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 45.95 (neutral) |
| vs SMA50 | Above (USD 34.85) |
| MACD | 0.84 (positive) |
Analyst Ratings (RIGL)
Wall Street analysts rate RIGL "None" based on 5 analysts, with a mean price target of USD 54.2 (range USD 40–81), per Nexqual as of July 25, 2026 at 06:46 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 54.2 |
| High Target | USD 81 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 3 / 2 / 0 |
Earnings (RIGL)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.01 |
| Revenue Estimate | $56.12M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.44 vs est 0.87 ▼ miss |
| 2025-12-31 | USD 1.12 vs est 1.2 ▼ miss |
| 2025-09-30 | USD 1.46 vs est 0.94 ▲ beat |
| 2025-06-30 | USD 3.28 vs est 1.41 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:46 UTC.
Financials & Fundamentals (RIGL)
| Total Revenue | $299.77M |
|---|---|
| Revenue Growth (YoY) | +10.30% |
| Gross Margin | +81.20% |
| Operating Margin | +20.21% |
| Profit Margin | +121.50% |
| ROE | +174.08% |
| Debt / Equity | 11.43 |
| Current Ratio | 2.62 |
| Total Cash | $146.68M |
| Total Debt | $45.72M |
| Free Cash Flow | $78.55M |
Source: Nexqual, July 25, 2026 at 06:46 UTC.
Financial Health Score (RIGL)
Nexqual rates Rigel Pharmaceuticals Inc's overall financial health "Strong" across five dimensions, as of July 25, 2026 at 06:46 UTC.
| Growth | Strong — Revenue +64% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 81%, operating 20% |
| Balance Sheet | Strong — $147M cash vs $46M debt, net cash position |
| Cash Flow | Strong — FCF $79M, 27% margin |
| Efficiency | Strong — ROE 174%, ROA 22.9% |
Ownership (RIGL)
| Insider Ownership | +3.39% |
|---|---|
| Institutional Ownership | +93.70% |
| Shares Outstanding | 18.50M |
| Float | 15.94M |
| Short % of Float | +17.53% |
Source: Nexqual, July 25, 2026 at 06:46 UTC.
Leadership (RIGL)
Rigel Pharmaceuticals Inc is led by Raul R. Rodriguez (age 64), President, CEO & Director, per Nexqual as of July 25, 2026 at 06:46 UTC.
| President, CEO & Director | Raul R. Rodriguez (age 64) |
|---|---|
| Executive VP & CFO | Dean L. Schorno (age 62) |
| Vice President of Marketing | Tarek Sallam |
Major Backers & Investors (RIGL)
Notable institutional backers of Rigel Pharmaceuticals Inc include Armistice Capital, LLC, American Century Companies Inc, Acadian Asset Management. LLC, according to Nexqual as of July 25, 2026 at 06:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 6.92% |
| American Century Companies Inc | 6.34% |
| Acadian Asset Management. LLC | 3.6% |
| LSV Asset Management | 3.25% |
| Marshall Wace LLP | 3.23% |
| Shaw D.E. & Co., Inc. | 2.41% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 13.42% |
| State Street | 9.55% |
| Vanguard Group | 8.16% |
| Geode Capital | 2.38% |
Source: Nexqual, July 25, 2026 at 06:46 UTC.
From Rigel Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- The litigation resulted from submission by Annora of an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market a generic version of TAVALISSE in the US.
- Grifols has launched TAVLESSE in the UK and certain countries in EU including Germany, France, Italy and Spain, and continues a phased rollout across the rest of EU.
Partnerships
- Global Strategic Partnership with Lilly In February 2021, we entered global exclusive license and strategic collaboration with Lilly to develop and commercialize ocadusertib (previously R552), an investigational, potent and selective RIPK1 inhibitor, for the treatment of non-central nervous system (non-CNS) diseases, and additional RIPK1 inhibitors for the treatment of central nervous system (CNS) diseases.
- Fostamatinib outside of the US We have a commercialization license agreement with Grifols for exclusive rights to commercialize fostamatinib for human diseases, and non-exclusive rights to develop, fostamatinib in their territory.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VSTM | Verastem, Inc. | USD 6.05 | ▲ 2.72% |
| CRIS | Curis, Inc. | USD 4.89 | ▼ 1.01% |
| LXRX | Lexicon Pharmaceuticals, Inc. | USD 2.29 | ▲ 1.78% |
| BCRX | BioCryst Pharmaceuticals, Inc. | USD 9.34 | ▼ 1.79% |
| VNDA | Vanda Pharmaceuticals Inc. | USD 5.18 | ▼ 3.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:46 UTC. This page is informational and not investment advice.